Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | RXRB | P28702 | 1/20 | 0.33 |
| ▸ | RXRG | P48443 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.32 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.31 |
| ▸ | ATR | Q13535 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1637598 | 0.77 | ALDH1A1 (0.38) | GAAALDH1A1LMNAPOLBRXRA | |
| SCHEMBL14279899 | 0.71 | GAA (0.30) | GAA | |
| SCHEMBL31496870 | 0.70 | CYP2C19 (0.36) | ALDH1A1LMNAPOLBMEN1KMT2A | |
| SCHEMBL22533326 | 0.68 | CYP4F2 (0.44) | ALDH1A1LMNAPOLBRXRARXRB | |
| SCHEMBL25183320 | 0.68 | CYP4F2 (0.42) | GAAALDH1A1LMNAPOLBRXRA | |
| SCHEMBL30904946 | 0.68 | GAA (0.39) | GAAALDH1A1LMNAPOLBRXRA | |
| SCHEMBL25183987 | 0.68 | CYP4F2 (0.37) | GAAALDH1A1LMNAPOLBRXRA | |
| SCHEMBL23684595 | 0.67 | ALDH1A1 (0.38) | GAAALDH1A1LMNAPOLBRXRA | |
| SCHEMBL18367241 | 0.65 | GAA (0.41) | GAAALDH1A1LMNAPOLBRXRA | |
| SCHEMBL7904174 | 0.65 | ALDH1A1 (0.40) | GAAALDH1A1LMNAPOLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1099702-B1 | Substituted morpholine derivatives and their use as therapeutic agents | MERCK SHARP & DOHME (GB) | 2004-10-06 | — | — | EP | disclosed |
| EP-1462450-A1 | Substituted morpholine derivatives and their use as therapeutic agents | MERCK SHARP & DOHME LTD. (GB) | 2004-09-29 | — | — | EP | disclosed |
| US-6329523-B1 | FOR ANTIBACTERIAL PHARMACEUTICAL USE, USEFUL FOR IDENTIFYING METAL CHELATING SPECIES FOR ?HEAVY METAL? THERAPY; IMAGING AGENTS | ISIS PHARMACEUTICALS, INC. | 2001-12-11 | — | — | US | disclosed |
| EP-0737192-B1 | SUBSTITUTED MORPHOLINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | MERCK SHARP & DOHME (GB) | 2001-10-31 | — | — | EP | disclosed |
| EP-1099702-A1 | Substituted morpholine derivatives and their use as therapeutic agents | MERCK SHARP & DOHME LTD. (GB) | 2001-05-16 | — | — | EP | disclosed |
| US-6197965-B1 | POLYARYLALKYLAMINO-SUBSTITUED PYRIDINE DERIVATIVES; DRUGS, MEDICINE, DIAGNOSTICS | ISIS PHARMACEUTICALS, INC. | 2001-03-06 | — | — | US | disclosed |
| US-6077954-A | COMPOUNDS ARE CONSTRUCTED TO INCLUDE A CENTRAL AROMATIC, ALIPHATIC, OR HETEROCYCLIC RING SYSTEM. ATTACHED TO THE CENTRAL RING SYSTEM ARE TWO LINEAR GROUPS HAVING NITROGENOUS MOIETIES THAT ARE DERIVATIZED WITH CHEMICAL FUNCTIONAL GROUPS. | ISIS PHARMACEUTICALS, INC. (US) | 2000-06-20 | — | — | US | disclosed |
| US-5612337-A | ANALGESIC COMPOUNDS FOR PRODRUGS | MERCK SHARP & DOHME LIMITED (GB) | 1997-03-18 | — | — | US | disclosed |